Skip to content
  • About
  • Shop
  • News
  • Contact Us
Search
NECA Logo
Menu
NET Nurse
Donate
What are NETs?
Patients & Carers
Healthcare Professionals
Get Involved
NET Nurse
Donate
What are NETs?
  • What are Neuroendocrine Cancers?
  • What are Pheos & Paras?
  • NET Symptoms
  • Causes
  • Treatments
  • Grades
National Action Plan
Patients & Carers
  • Patient & Carer Support
  • Patient Resources
  • Optimal Care Pathway
  • NET Nurse
  • Patient Stories
  • Share your Story
  • Australian NET Specialists
  • Clinical Trials
  • Living with NETS
National Action Plan
Healthcare Professionals
  • Optimal Care Pathway
  • Professional Learning
  • Patient Referral
  • Clinical Trials
  • NET Symptoms
  • Australian NET Specialists
  • Request an In-Service
  • PLANET Registry
  • Order Booklets & Resources
National Action Plan
Get Involved
  • Advocate for Us
  • Share your Story
  • Donate
  • Fundraise
  • Events
  • In Memoriam
  • Corporate Partners
  • Gifts & Wills
  • Volunteer
National-Action-Plan-1.png
NET Nurse
Donate

Home » Research » Breakthrough research into PNET genome sequencing

Breakthrough research into PNET genome sequencing

  • February 16, 2017
Researchers found as many as one in five patients with pancreatic neuroendocrine tumours (PanNETs) had a clear genetic predisposition for their cancers, even though they had no family history of the disease.

The findings, published this week in the journal Nature, offer the prospect of one day being able to identify people at risk of these cancers, as well as aggressive forms of the disease, and who might respond to current or new targeted therapies.
The breakthrough is the work of researchers at the University of Melbourne, Garvan Institute of Medical Research, QIMR Berghofer Medical Research Institute, The University of Queensland and the Children’s Medical Research Institute, as well as European and US teams.They carried out whole genome sequencing of tumours from 100 Australian patients recruited through the Australian Pancreatic Cancer Genome Initiative (APGI).

Study co-leader Professor Sean Grimmond, the University of Melbourne’s Bertalli Chair of Cancer Medicine, said researchers were surprised to find striking similarities between the genetic drivers of PanNETs and other cancers.
“We found that the MUTYH and BRCA2 gene mutations, normally associated with colon and breast cancers, also appear to play an important role in PanNETs,” Professor Grimmond said.
“This raises exciting possibilities for how we treat this disease in the future."
Study co-leader Dr Nicola Waddell, of QIMR Berghofer, said people without a family history of cancer could still carry a faulty gene that increases their risk of developing this tumour.
“The genetic variants we’ve identified may help to predict how aggressive each patient’s tumour is and what sort of treatment they’re likely to benefit from,” she said.
“In the future, patients at risk of this rare pancreatic cancer could be identifiable through genetic screening.”

To read the full article please download here

https://neuroendocrine.org.au/wp-content/uploads/2020/03/nature21063.pdf

Share this post

Subscribe to our eNews

Stay up to date on news and events, clinical trials and new research on neuroendocrine cancers.

Recent posts

Online survey for NET patients

September 26, 2023

Medicines Australia PharmAus event in Canberra

September 26, 2023

INCA Annual Summit 2023

September 26, 2023

Have your say on #EndGenderBias in Australia’s healthcare system

September 19, 2023
Categories
  • Advocacy
  • Awareness
  • Community Events
  • Education
  • Events
  • Fundraising
  • General
  • In The Media
  • News
  • Research
  • Unicorn Events
PrevPreviousSenate Committee – Funding for research into low survival cancers
NextUF Attends 14th Annual ENETs ConferenceNext

Related Posts

The Australian Cancer Plan

Shaping the future of cancer control together   We are pleased to send you this update on the Australian Cancer Plan, the first national 10-year

Impact of Nutritional Status on Gastroenteropancreatic Neuroendocrine Tumors (GEP-NET) Aggressiveness

Read full report

Peter MacCallum Cancer Centre – Recruiting NET health professionals for International Delphi survey

Recruiting NET health professionals for International Delphi survey Development of a neuroendocrine tumour (NET) nutrition-risk screening tool to identify patients requiring nutrition intervention and education

Molecular imaging phenotyping for selecting and monitoring radioligand therapy of neuroendocrine neoplasms

Read full report

View All

Make a difference

How much do you wish to donate?
$50
$100
$250
$500
$1000
Other

Subscribe to Newsletter

NECA Logo
registered charity badge

What are NETs

  • What Are Neuroendocrine Cancers?​
  • What Are Pheos & Paras?
  • National Patient Awareness
  • What Are Neuroendocrine Cancers?​
  • What Are Pheos & Paras?
  • National Patient Awareness

Patients & Carers

  • Patient & Carer Support
  • Patient Resources
  • Optimal Care Pathway
  • NET Nurse
  • National Action Plan
  • Patient Stories
  • Share your story
  • Australian NET Specialists
  • Clinical Trials
  • Living with NETS
  • Patient & Carer Support
  • Patient Resources
  • Optimal Care Pathway
  • NET Nurse
  • National Action Plan
  • Patient Stories
  • Share your story
  • Australian NET Specialists
  • Clinical Trials
  • Living with NETS

Healthcare Professionals

  • Optimal Care Pathway
  • Professional Learning
  • Patient Referral
  • Clinical Trials
  • NET Symptoms
  • Australian NET Specialists
  • Request an In-Service
  • PLANET Registry
  • Order Booklets & Resources
  • Optimal Care Pathway
  • Professional Learning
  • Patient Referral
  • Clinical Trials
  • NET Symptoms
  • Australian NET Specialists
  • Request an In-Service
  • PLANET Registry
  • Order Booklets & Resources

Get Involved

  • Advocate for us
  • Share your story
  • Donate
  • Fundraise
  • Events
  • In Memoriam
  • Corporate Partners
  • Gifts & Wills
  • Volunteer
  • Advocate for us
  • Share your story
  • Donate
  • Fundraise
  • Events
  • In Memoriam
  • Corporate Partners
  • Gifts & Wills
  • Volunteer
All charity donations to NeuroEndocrine Cancer Australia may be tax-deductible in Australia.

Registered Charity CFN 202607
© 2023 NeuroEndocrine Cancer Australia
  • Website by Five Creative
Twitter Facebook Youtube Instagram Linkedin

What's on?

How to identify a neuroendocrine cancer when it’s not part of the typical line up. A RACGP & ACN CPD accredited course.

Share this course with your healthcare professional so they can enrol in this free online course and learn more about how to diagnose and treat NETs in general practice.

Learn More